Synthetic approaches for dissection of the signalling response heterogeneity and targeted therapeutic use of type-1 interferons

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1072825

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Type-1 interferons have been used to treat at least 14 diseases, including cancer, hepatitis and multiple sclerosis. Differing success of treatment and serious side effects felt by patients, however, have limited use of these otherwise powerful therapies. I aim to better understand the responses different cells have to interferons to improve their utility in the clinic. Also, I will develop approaches to target interferons to the site of disease, reducing the side effects felt by patients.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2021

Funding Scheme: Early Career Fellowships

Funding Amount: $375,974.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Signal Transduction

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biosensor | biotechnology | cancer biology | fusion protein | interferon non-responders | interferon side-effects | interferon-alpha (IFN-alpha) | signal transduction | targeted therapy | variability

Related Links